Pharma Companies Overlook Patent Cliff, but Don't Fall Yet
By Staff Reports
Monday, October 29, 2012
Merck & Co. Inc., of Whitehouse Station, N.J., shrugged off the worst effects of the August 2012 loss of market exclusivity for its blockbuster drug Singulair (montelukast sodium) in the U.S.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.